Skip to main content
Signal8

Regeneron Reports Third Quarter 2026 Financial and Operating Results

$REGNPress releaseOct 30, 2026, 6:30 AM ET

Regeneron posted Q3 2026 revenue of $5.116 billion, up 36% year-over-year, with GAAP EPS of $18.45 (+35%) and non-GAAP EPS of $20.07 (+70%). Dupixent global net sales rose 35% to $6.54 billion and EYLEA HD U.S. sales jumped 62% to $699 million, while legacy EYLEA U.S. sales fell 41% on competition and patient transition to EYLEA HD.

Key figures

Eps
18.45
Revenue
5116000000
Guidance
FY2026: GAAP R&D $6.600-$6.735B (raised); non-GAAP R&D $6.050-$6.150B (raised); GAAP SG&A $2.730-$2.860B (lowered); non-GAAP SG&A $2.400-$2.500B (lowered); GAAP gross margin ~80% (raised from 78-79%); non-GAAP gross margin ~86% (raised from 84-85%)
Revenue Yoy
36%
Libtayo growth
51%
Dupixent growth
35%
Eylea us change
-41%
Gaap eps diluted
18.45
Buyback remaining
2200000000
Dividend per share
0.94
Eylea hd us growth
62%
Eylea us net sales
400000000
Nongaap net income
2150000000
Nongaap eps diluted
20.07
Buybacks nine months
2300000000
Eylea hd us net sales
699000000
Sanofi upfront payment
1000000000
Libtayo global net sales
550000000
Free cash flow nine months
2904300000
Sanofi collaboration revenue
2724000000
Sanofi future milestones potential
7000000000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.